Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrophage-activating factor extracted from mycoplasmas.

M Takema1, S Oka, K Uno

  • 1Department of Zoology, Faculty of Science, Kyoto University, Japan.

Cancer Immunology, Immunotherapy : CII
|January 1, 1991
PubMed
Summary

Mycoplasmas activate macrophages to kill tumors, even after treatment. A mycoplasma factor (Mf-B), distinct from lipopolysaccharides, enhances this tumoricidal activity with interferon gamma (IFN gamma).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of collateral pathways established after lymphadenectomy in rats.

Lymphology·2018
Same author

Traumatic limb amputations at a level I trauma center.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
Same author

The impact of anemia in moderate to severe traumatic brain injury.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
Same author

The impact of ETOH intoxication on the development of admission coagulopathy after traumatic brain injury: a prospective evaluation.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
Same author

Dalteparin versus Enoxaparin for the prevention of venous thromboembolic events in trauma patients.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
Same author

The need for early angiography in patients with penetrating renal injuries.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016

Area of Science:

  • Immunology
  • Microbiology
  • Cell Biology

Background:

  • Mycoplasmas are known to interact with host immune cells.
  • Interferon gamma (IFN gamma) is a key cytokine in immune responses.
  • Macrophages (M theta) play a crucial role in tumor surveillance and elimination.

Purpose of the Study:

  • To investigate the potential of mycoplasmas and their components to activate macrophages for tumoricidal activity.
  • To characterize the nature of the macrophage-activating factor from mycoplasmas.
  • To elucidate the mechanism of mycoplasma-induced macrophage activation.

Main Methods:

  • Treatment of mycoplasmas and extraction of macrophage-activating factor (Mf-B).
  • Co-incubation of macrophages with Mf-B and IFN gamma.

Related Experiment Videos

  • Assessment of macrophage tumoricidal activity and cytokine production.
  • Comparison of Mf-B activity in different mouse strains to differentiate from lipopolysaccharide effects.

    • Main Results:

    • Mycoplasmas, along with IFN gamma, effectively activated macrophages to become tumoricidal.
    • The macrophage-activating capacity of mycoplasmas was resistant to heat, acid, alkali, and trypsin treatment.
    • Mf-B, extracted from mycoplasmas, activated macrophages in the presence of IFN gamma, with activity independent of lipopolysaccharide response pathways.
    • Macrophage cytotoxicity was dependent on L-arginine, and Mf-B induced tumor necrosis factor, enhanced by IFN gamma.

    Conclusions:

    • Mycoplasmas possess a heat-stable factor (Mf-B) that activates macrophages for tumoricidal functions, distinct from lipopolysaccharides.
    • The mechanism involves L-arginine metabolism and induction of tumor necrosis factor, modulated by IFN gamma.
    • This finding suggests a potential therapeutic strategy for cancer immunotherapy using mycoplasma-derived factors.